Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: A two‐year follow‐up study
Authors:
Open Access
- 14 May 2009
- journal article
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 63 (3) , 374-384
Abstract
Aim: To examine the effect of neuropsychiatric symptoms on longitudinal changes in the quality of life (QOL) of patients with Alzheimer disease (AD).Methods: First, we investigated whether neuropsychiatric symptoms at baseline predict changes in the QOL of AD patients over time. Then we examined the associations between changes in neuropsychiatric symptoms and changes in QOL. QOL was assessed using the Japanese version of the Quality of Life–Alzheimer Disease (QOL–AD) scale and other clinical instruments [the Mini‐Mental State Examination, The Neuropsychiatry Inventory (NPI)] at baseline and again two years later in 96 AD patients among 140 AD patients at baseline. We performed a multiple regression analysis of the baseline QOL–AD score, NPI score (mood, psychosis, and euphoria factor), Mini‐Mental State Examination score, and other clinical instrument variables (e.g. Activities‐of‐Daily‐Living scores) to determine their contribution to the change in QOL–AD score.Results: While the total QOL–AD score based on the patients' responses did not change significantly, the total QOL–AD score derived from the caregivers' responses declined. Both the Activities‐of‐Daily‐Living score and the mood factor of the NPI score predicted the change in the QOL–AD score as assessed by the caregivers' responses. In addition, there was a significant correlation between the changes in two factors of the NPI, i.e. the mood and psychosis factor, and the changes in the QOL–AD score based on the caregivers' responses.Conclusions: The presence of specific neuropsychiatric symptoms (mood and psychosis symptoms) was associated with changes in the QOL of AD patients during the follow‐up period.Keywords
This publication has 30 references indexed in Scilit:
- Depression and apathy affect functioning in community active subjects with questionable dementia and mild Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2006
- A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2005
- The course of neuropsychiatric symptoms in dementia. Part I: findings from the two‐year longitudinal Maasbed studyInternational Journal of Geriatric Psychiatry, 2005
- The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub‐syndromes and the influence of clinical variablesInternational Journal of Geriatric Psychiatry, 2005
- Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2004
- The Validity of the MMSE and SMQ as Screening Tests for Dementia in the Elderly General Population – A Study of One Rural Community in JapanDementia and Geriatric Cognitive Disorders, 2000
- The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled TrialDementia and Geriatric Cognitive Disorders, 1996
- The Neuropsychiatric InventoryNeurology, 1994
- Quality of Life in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984